Biotechnology Industry · global
Ferring plans to acquire Gameto for up to $1.3825 billion, expanding into egg in vitro maturation technology
Maturing eggs in the laboratory could reduce the hormonal burden of assisted reproductive treatment. Ferring plans to add this cell engineering technology to its reproductive medicine portfolio, but the deal has yet to close, and the core product still faces clinical and regulatory evaluation in the United States.
Repeated hormone injections and trips to the clinic are burdens many people seeking to conceive must bear during assisted reproductive treatment. Gameto, which aims to move part of the egg maturation process into the laboratory, has now received an acquisition proposal from a major reproductive medicine company: Ferring announced on October 27 that it had signed an agreement to acquire the biotech company for up to $1.3825 billion, bringing its cell engineering platform into Ferring’s existing international reproductive medicine business.
That figure represents the deal’s potential maximum value. According to the companies’ announcements, the total value depends on development, regulatory and commercial milestones. Reports from BioPharma Dive and European Biotechnology indicate that the upfront payment has not been disclosed, nor has a closing date. The two companies will continue to operate independently until the closing conditions are met.
One of the core technologies in the acquisition is Fertilo. It uses induced pluripotent stem cells to produce ovarian support cells, which are then cultured together with immature eggs retrieved from patients to mimic the environment that supports egg maturation within the ovary. These engineered cells play a supporting role; the eggs still come from the patients. Only after the eggs mature do they proceed to steps such as fertilization or cryopreservation.
This approach builds on egg in vitro maturation (IVM) technology. Conventional in vitro fertilization treatment typically uses about two weeks of hormone injections to stimulate eggs to mature inside the body. Fertilo is designed to shorten the stimulation period before egg retrieval, allowing the subsequent maturation process to take place in a culture environment. Reducing injections and treatment burden is a development goal, but this alone does not establish that all patients will experience the same degree of improvement or achieve pregnancy outcomes comparable to those of conventional treatment.
Clinical evidence remains critical. According to BioPharma Dive, Fertilo is undergoing a Phase 3 trial in the United States. Both the companies’ acquisition announcements and American Pharmaceutical Review explicitly state that Gameto’s in vitro maturation programs remain investigational in the United States and have not been approved by the Food and Drug Administration (FDA). The deal announcement also provided no new efficacy or safety results, and the acquisition agreement itself does not change the product’s regulatory status.
For Ferring, which already markets fertility hormone products such as Menopur, the deal would extend its activities into the culture environment for egg maturation. Gameto also has Deovo, an in vitro model of the female reproductive system for drug development, and Ameno, a cell therapy program aimed at delaying menopause. These research and development efforts, however, cannot be regarded as proven clinical applications. If the transaction closes, it will bring established international operational resources to these technologies. Whether they can truly reduce the burden on patients will still depend on subsequent trials, the scope of approvals and real-world use.